Lupin’s stock rises in the wake of USFDA nod for Aurangabad facility
With the news that Lupin, engaged in producing, developing and marketing a range of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs) across the world, has received the Establishment Inspection Report (EIR) from USFDA for its Aurangabad facility, the company’s stock picked up momentum and was trading at Rs 948.3, up by 2.76% on the BSE at 0916 hours.
The inspection was carried out in April 2017 and now stands closed.
The stock has adjusted 52-week high at Rs 1,590 (September 9, 2016) and adjusted 52-week low at Rs 920 (August 21, 2017) on the BSE. The share price of the company has witnessed turnover of Rs 2.14 crore with quantity of 23,000 at 0921 hours.